Price movement over the last 24 hours
Abeona Therapeutics Inc vs Ford Motor Company — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while Ford Motor Company trades at $13.5 (market cap $54.03B). The key difference: Ford Motor Company is far larger — about 144.7× Abeona Therapeutics Inc's market cap, and Ford Motor Company pays a 4.42% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | F | |
|---|---|---|
Market Cap | $373.32M | $54.03B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $17.44 |
52-Week Low | $4.17 | $10.82 |
Enterprise Value | $228.22M | $183.06B |
Dividend Yield | — | 4.42% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Ford Motor Company (F) trades at $13.57, up 1.65% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative net income margin and ROE. Recent developments include a strategic semiconductor supply agreement with Micron and vehicle recalls affecting over 110,000 Mustang models. Operating cash flow remains robust at $21.28 billion for 2025, though net income turned negative at -$8.18 billion.
Ford presents a value opportunity with attractive valuation ratios (P/E 11.84, P/S 0.29) but faces significant execution risks. The stock trades below analyst consensus target of $15.00, offering potential upside, though recent sales declines and profitability concerns warrant caution. Key catalysts include EV strategy execution and truck demand strength, while risks include competitive pressures and operational challenges.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →